We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Celera Licenses Genetic-Analysis Products for Diagnostic Development

By LabMedica International staff writers
Posted on 05 May 2009
Perlegen Sciences (Mountain View, CA, USA) and Celera (Alameda, CA, USA) have entered into a nonexclusive license agreement focused on methods of genetic analysis central to creating diagnostic products. More...
The agreement grants Celera use of Perlegen intellectual property as well as use of Perlegen's specific predictive genetic markers on chromosome 9p21 for coronary heart disease, to be included in products marketed by Celera. Financial terms of the agreement were not disclosed.

Perlegen's genetic-analysis intellectual property covers the combination of multiloci markers to create diagnostic products for determining an individual's predisposition to multifactorial disease or for ascertaining an appropriate course of treatment. It should allow Celera to detect genetic markers for multifactorial traits and tightly linked haplotype blocks, facilitate optimal matching of patient cases and controls, and provide methods for managing the massive data sets that accompany these analyses.

"We believe access to these highly replicated markers, which complement our internal proprietary genetic discoveries in cardiovascular disease such as KIF6 and LPA, furthers Celera's commitment to be a leading provider of genetic tests used routinely in personalizing disease management," said Kathy Ordonez, CEO of Celera. "These markers are expected to enhance our focus on cardiovascular disease while expanding our menu into diabetes and metabolic syndrome. We believe the additional pharmacogenomic aspects of these markers allow us the potential to personalize disease management that may further improve patient compliance with treatments for cardiovascular disease and diabetes."

Perlegen's objective is to discover and commercialize genetic variations that can make a difference to patients and physicians. The company's expertise is in understanding human genetic variation within and across diverse patient populations and in conducting studies aimed at identifying those variations that are predictive of drug response, including both toxicity and efficacy. The company's lead product, the MammaPLUS breast cancer risk stratifier, scheduled for launch in the second half of 2009, is a novel diagnostic test containing all of the currently validated and replicated common genetic variations associated with an increased risk for breast cancer.

Related Links:

Perlegen Sciences
Celera



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Researchers have developed the first ever test for early detection of multiple sclerosis (Photo courtesy of 123RF)

Blood Test Detects Multiple Sclerosis Risk Years Before Onset of Symptoms

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that affects around 2.8 million people worldwide. Its development is linked to immunological processes triggered... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.